<DOC>
	<DOCNO>NCT01005758</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This phase II trial study side effect combination chemotherapy see well work treat adult patient newly diagnose acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine feasibility , toxicity , efficacy high-risk pediatric treatment regimen adult patient newly diagnose acute lymphoblastic leukemia ( ALL ) . - To explore relative toxicity pegaspargase IV . - To explore relative efficacy toxicity add imatinib mesylate multi-agent chemotherapy patient Philadelphia chromosome-positive ALL . Secondary - To estimate complete remission ( CR ) rate end induction therapy calculate correspond 90 % confidence interval ( CI ) . - To estimate disease-free survival ( DFS ) , define time achieve CR first disease recurrence death , subset patient achieve CR end induction therapy . - To estimate overall survival ( OS ) , define time study entry death cause , patient . - To calculate median , 2-year , 3-year DFS OS rate correspond 95 % CI 's . - To evaluate prognostic significance prednisone prophase response , minimal residual disease various time point , frequency type tyrosine kinase mutation , gene expression profile diagnosis . OUTLINE : This multicenter study . - Steroid prophase therapy ( patient receive steroid within past 7 day ) : Patients receive cytarabine intrathecally ( IT ) day 0 1 methylprednisolone IV 3 time daily day 1-3 . - Induction therapy ( week 1-4 ) : Patients receive vincristine sulfate IV day 4 , 11 , 18 , 25 ; doxorubicin hydrochloride IV day 4 5 ; methotrexate IV day 6 ; pegaspargase IV 1 hour day 7 ; prednisone prednisolone orally 2-3 time daily methylprednisolone IV 3 time daily day 4-32 . Patients also receive methotrexate , cytarabine , hydrocortisone IT day 18 methotrexate IT day 32 . After completion induction therapy , patient document complete remission ( CR ) proceed consolidation IA therapy ( group A ) . Patients partial remission proceed consolidation IC therapy ( group B ) . Patients refractory disease remove study . - Consolidation I therapy ( week 5-13 ) : Patients assign 1 2 group accord CR status . - Group A ( patient achieve CR day 32 patient delayed recovery ) : - Consolidation IA therapy ( week 5-7 ) : Patients receive vincristine sulfate IV , doxorubicin hydrochloride IV , methotrexate IT , high-dose methotrexate IV day 1 . Patients also receive oral mercaptopurine daily day 1-14 . Patients proceed consolidation IB therapy . - Consolidation IB therapy ( week 8-10 ) : Patients receive cyclophosphamide IV 1 hour methotrexate IT day 1 , low-dose cytarabine IV subcutaneously ( SC ) day 2-5 9-12 , oral mercaptopurine daily day 1-14 . Patients proceed consolidation IC therapy . - Consolidation IC therapy ( week 11-13 ) : Patients receive high-dose cytarabine IV 3 hour twice daily day 1 2 , etoposide phosphate IV 2 hour day 3-5 , oral dexamethasone twice daily day 1-5 . Patients also receive pegaspargase IV 1 hour every 2 week begin day 8 continue CNS therapy consolidation II therapy total 15 dos administer . After completion consolidation IC therapy , patient proceed CNS therapy . - Group B ( patient fail enter CR 32 day multi-agent induction chemotherapy ) : - Consolidation IC therapy ( week 5-7 ) : Patients receive high-dose cytarabine IV 3 hour twice daily day 1 2 , etoposide phosphate IV 2 hour day 3-5 , oral dexamethasone twice daily day 1-5 . Patients achieve CR end consolidation IC therapy proceed consolidation IA therapy . Patients &gt; 5 % blast count end consolidation IC therapy remove study . - Consolidation IA therapy ( week 8-10 ) : Patients receive vincristine sulfate IV , doxorubicin hydrochloride IV , methotrexate IT , high-dose methotrexate IV day 1 . Patients also receive oral mercaptopurine daily day 1-14 . Patients proceed consolidation IB therapy . - Consolidation IB therapy ( week 11-13 ) : Patients receive cyclophosphamide IV 1 hour methotrexate IT day 1 , low-dose cytarabine IV SC day 2-5 9-12 , oral mercaptopurine daily day 1-14 . Patients also receive pegaspargase IV 1 hour every 2 week begin day 8 continue CNS therapy consolidation II therapy total 15 dos administer . After completion consolidation IB therapy , patient proceed CNS therapy . - CNS therapy ( week 14-16 ) : Patients receive vincristine sulfate IV doxorubicin hydrochloride IV day 1 , oral mercaptopurine daily day 1-14 , oral dexamethasone twice daily day 1-5 , pegaspargase describe consolidation I therapy . Patients also receive methotrexate , cytarabine , hydrocortisone IT twice weekly 4 dos undergo cranial irradiation daily 8-10 day . After completion CNS therapy , patient proceed consolidation II therapy . - Consolidation II therapy ( week 17-43 ) : Patients receive vincristine sulfate IV doxorubicin hydrochloride IV day 1 , oral mercaptopurine daily day 1-14 , oral dexamethasone twice daily day 1-5 , pegaspargase describe consolidation I therapy . Treatment repeat every 3 week patient receive cumulative dosage 300 mg/m^2 doxorubicin hydrochloride 30 post-remission week pegaspargase administer . When patient complete doxorubicin hydrochloride , receive methotrexate IV weekly ( except week receive methotrexate IT ) . Patients also receive methotrexate , cytarabine , hydrocortisone IT every 18 week ( first dose give 18 week first lumbar puncture administer CNS therapy ) . After completion consolidation II therapy , patient proceed continuation therapy . - Continuation therapy ( week 44-113 ) : Patients receive vincristine sulfate IV day 1 ; methotrexate IV day 1 , 8 , 15 ; oral mercaptopurine daily day 1-14 ; oral dexamethasone twice daily day 1-5 . Treatment repeat every 3 week total 104 week ( 24 month ) continue CR . Patients also receive methotrexate , cytarabine , hydrocortisone IT every 18 week . Patients receive methotrexate IV week receive methotrexate IT . Patients Philadelphia chromosome-positive disease bcr-abl translocation molecular study also receive oral imatinib mesylate daily begin day 14 induction therapy continue completion continuation therapy . These patient proceed allogeneic stem cell transplantation soon feasible base donor availability patient 's medical status . Bone marrow , peripheral blood , sample collect periodically research study ( include minimal residual disease analysis , gene expression profiling , tyrosine kinase sequence ) . After completion study treatment , patient follow monthly 6 month , every 2 month 6 month , every 4 month 1 year , every 6 month 1 year , annually thereafter .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute lymphoblastic leukemia ( ALL ) No known mature Bcell ALL* , define presence surface immunoglobulin , L3 morphology , ( 8 ; 14 ) ( q24 ; q32 ) , ( 8 ; 22 ) , ( 2 ; 8 ) Patients Tcell surface marker ( 8 ; 14 ) ( q24 ; q11 ) eligible NOTE : *Patients mature Bcell ALL remove study soon diagnosis make . No secondary ALL ( i.e. , ALL arise another malignancy ) PATIENT CHARACTERISTICS : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known HIV positivity ( HIV test require ) No comorbid medical condition would , investigator 's opinion , make participation study adherence study guideline compromise study objectives No active psychiatric mental illness would make give informed consent careful clinical followup unlikely PRIOR CONCURRENT THERAPY : No prior antileukemic therapy except â‰¤ 1 week steroid , emergent radiotherapy mediastinum , hydroxyurea , emergent leukapheresis Patients receive steroid within past 7 day eligible receive steroid prophase therapy study No concurrent chronic steroid antimetabolite therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia</keyword>
	<keyword>L1 adult acute lymphoblastic leukemia</keyword>
	<keyword>L2 adult acute lymphoblastic leukemia</keyword>
	<keyword>T-cell adult acute lymphoblastic leukemia</keyword>
</DOC>